I don’t agree. To the contrary, I think LibiGel has a good chance to be a big-selling drug.
The addressable market—women who want better sex—is obviously a large one, and low-dose testosterone has proven efficacy in raising female libido. If not for the FDA’s near-maniacal obsession with the safety of “lifestyle” drugs, LibiGel and Intrinsa, a similar drug from PG, would already be on the market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.